Latvij\u0101 turpin\u0101s gripas epid\u0113mija, un 2025. gada 51. ned\u0113\u013cas monitoringa dati liecina par turpm\u0101ku saslimst\u012bbas pieaugumu. Pacientu \u012bpatsvars ar elpce\u013cu infekciju simptomiem ambulatoraj\u0101s \u0101rstniec\u012bbas iest\u0101d\u0113s 51.ned\u0113\u013c\u0101 sasniedza 26 % no visiem \u0101rstu apmekl\u0113jumiem. Monitoringa dati liecina, ka saslimst\u012bba ar gripu turpin\u0101ja palielin\u0101ties un vid\u0113j\u0101 gripas intensit\u0101te p\u0101rsniedz p\u0113d\u0113jo piecu sezonu maksim\u0101lo r\u0101d\u012bt\u0101ju.<\/p>\n
Gripa kl\u012bniski noteikta 528 pacientiem, un vid\u0113j\u0101 saslimst\u012bbas intensit\u0101te sasniedza 795,0 gad\u012bjumus uz 100 000 iedz\u012bvot\u0101ju, kas ir par 6,6 % vair\u0101k nek\u0101 iepriek\u0161\u0113j\u0101 ned\u0113\u013c\u0101 (746,0 uz 100 000 iedz\u012bvot\u0101ju). Saslimst\u012bbas pieaugums kopum\u0101 nov\u0113rots vis\u0101s vecuma grup\u0101s. T\u0101pat k\u0101 cit\u0101s sezon\u0101s, augst\u0101ka saslimst\u012bba ar gripu re\u0123istr\u0113ta b\u0113rniem l\u012bdz 14 gadu vecumam.<\/p>\n
Gripas gad\u012bjumi 51. ned\u0113\u013c\u0101 re\u0123istr\u0113ti vis\u0101s 10 monitoringa teritorij\u0101s. Visaugst\u0101k\u0101 gripas intensit\u0101te konstat\u0113ta Jelgav\u0101 \u2013 2867,4 gad\u012bjumi uz 100 000 iedz\u012bvot\u0101ju. Augsti saslimst\u012bbas r\u0101d\u012bt\u0101ji re\u0123istr\u0113ti ar\u012b J\u0113kabpils novad\u0101 (1951,0 uz 100 000 iedz\u012bvot\u0101ju), R\u0113zekn\u0113 (1123,2 uz 100 000 iedz\u012bvot\u0101ju), Gulbenes novad\u0101 (1031,2 uz 100 000 iedz\u012bvot\u0101ju) un R\u012bg\u0101 (713,4 uz 100 000 iedz\u012bvot\u0101ju), kas liecina par gripas pla\u0161u izplat\u012bbu vis\u0101 valst\u012b.<\/p>\n
Ar citu ak\u016btu elpce\u013cu infekciju simptomiem ambulatoraj\u0101s iest\u0101d\u0113s ned\u0113\u013cas laik\u0101 v\u0113rsu\u0161ies 1125 pacienti jeb vid\u0113ji 1693,9 gad\u012bjumi uz 100 000 iedz\u012bvot\u0101ju, kas ir par 13,7 % vair\u0101k nek\u0101 iepriek\u0161\u0113j\u0101 ned\u0113\u013c\u0101. Pneimoniju gad\u012bjum\u0101 v\u0113r\u0161an\u0101s ambulatoraj\u0101s iest\u0101d\u0113s samazin\u0101jusies \u2013 re\u0123istr\u0113ti 52,7 gad\u012bjumi uz 100 000 iedz\u012bvot\u0101ju, kas ir par 36,9 % maz\u0101k nek\u0101 50. ned\u0113\u013c\u0101.<\/p>\n
Stacion\u0101raj\u0101s \u0101rstniec\u012bbas iest\u0101d\u0113s\u00a0pag\u0101ju\u0161aj\u0101 ned\u0113\u013c\u0101\u00a0stacion\u0113ti\u00a0278 pacienti ar smagu ak\u016btu respiratoru infekciju\u00a0(SARI).\u00a0SARI pacientu \u012bpatsvars no kop\u0113j\u0101 uz\u0146emto pacientu skaita saglab\u0101j\u0101s\u00a0iepriek\u0161\u0113j\u0101s ned\u0113\u013cas l\u012bmen\u012b \u2013\u00a06,3 %.\u00a0No visiem\u00a0stacion\u0113tajiem\u00a0SARI pacientiem 42,1 % bija vecuma grup\u0101 65 gadi un vair\u0101k, kas apstiprina paaugstin\u0101to smagas slim\u012bbas risku senioriem.\u00a0Nacion\u0101laj\u0101 mikrobiolo\u0123ijas references laboratorij\u0101 51. ned\u0113\u013c\u0101 uz gripas v\u012brusiem izmekl\u0113ti 456 kl\u012bniskie paraugi, no kuriem 78 jeb 17,1 % gad\u012bjumu apstiprin\u0101ta gripa. Sal\u012bdzin\u0101jum\u0101 ar iepriek\u0161\u0113jo ned\u0113\u013cu laboratoriski apstiprin\u0101to gripas paraugu \u012bpatsvars ir samazin\u0101jies, tom\u0113r kop\u0113j\u0101 saslimst\u012bba ar gripu joproj\u0101m saglab\u0101jas augsta.\u00a0Kop\u0161 sezonas s\u0101kuma laboratoriski apstiprin\u0101ti\u00a0tikai A tipa gripas v\u012brusi,\u00a0domin\u0113jot\u00a0A(H3)\u00a0apak\u0161tipam\u00a0(81,2%).<\/p>\n
Covid-19 saslimst\u012bbas situ\u0101cija 51. ned\u0113\u013c\u0101 saglab\u0101j\u0101s stabila. Covid-19 pozit\u012bvo paraugu \u012bpatsvars bija 5,7 %, l\u012bdz\u012bgs iepriek\u0161\u0113j\u0101s ned\u0113\u013cas r\u0101d\u012bt\u0101jam. Slimn\u012bc\u0101s uz\u0146emti 42 Covid-19 pacienti, un kopum\u0101 stacion\u0101ros \u0101rst\u0113ju\u0161ies 75 pacienti ar apstiprin\u0101tu infekciju, no kuriem 31 pacientam Covid-19 bija pamata diagnoze. Re\u0123istr\u0113ti \u010detri n\u0101ves gad\u012bjumi pacientiem ar Covid-19 infekciju. Notek\u016bde\u0146u monitoringa dati liecina, ka SARS-CoV-2 RNS koncentr\u0101cija Latvij\u0101 kopum\u0101 pieaug.<\/p>\n
Eirop\u0101 gripas izplat\u012bba turpina palielin\u0101ties. PVO Eiropas re\u0123iona uzraudz\u012bbas dati liecina, ka paaugstin\u0101ti gripas un ak\u016btu elpce\u013cu infekciju r\u0101d\u012bt\u0101ji nov\u0113roti liel\u0101kaj\u0101 da\u013c\u0101 valstu, un vair\u0101k nek\u0101 div\u0101s tre\u0161da\u013c\u0101s zi\u0146ojo\u0161o valstu gripas intensit\u0101te ir vid\u0113ja vai augsta. Domin\u0113jo\u0161ais cirkul\u0113jo\u0161ais v\u012bruss Eirop\u0101 ir A(H3N2), un augst\u0101kais pozit\u012bvo testu \u012bpatsvars tiek konstat\u0113ts b\u0113rniem vecum\u0101 no 5 l\u012bdz 14 gadiem, k\u0101 ar\u012b pieaug\u00a0stacion\u0113to\u00a0pacientu skaits senioru vid\u016b.<\/p>\n
Gripa smag\u0101k norit senioriem, cilv\u0113kiem ar hronisk\u0101m saslim\u0161an\u0101m, gr\u016btniec\u0113m un maziem b\u0113rniem. Vakcin\u0101cija pret gripu joproj\u0101m ir visefekt\u012bv\u0101kais veids, k\u0101 pasarg\u0101t sevi no smagas slim\u012bbas gaitas un komplik\u0101cij\u0101m. \u0145emot v\u0113r\u0101, ka imunit\u0101te veidojas 10\u201314 dienu laik\u0101 un gripas izplat\u012bba parasti turpin\u0101s l\u012bdz pavasarim, vakcin\u0113ties ir lietder\u012bgi ar\u012b epid\u0113mijas laik\u0101.\u00a0SPKC t\u012bmek\u013cvietn\u0113 pieejams saraksts<\/a>\u00a0ar \u0101rstniec\u012bbas iest\u0101d\u0113m, kur riska grupu pacienti var sa\u0146emt valsts apmaks\u0101tu vakcin\u0101ciju pret gripu, ja\u00a0pacienta \u0123imenes\u00a0\u0101rsta praks\u0113 vakc\u012bnas vairs nav pieejamas.<\/p>\n Lai mazin\u0101tu infic\u0113\u0161an\u0101s risku, iedz\u012bvot\u0101ji aicin\u0101ti iev\u0113rot elpce\u013cu higi\u0113nu, bie\u017ei mazg\u0101t un dezinfic\u0113t rokas, regul\u0101ri v\u0113din\u0101t telpas, izvair\u012bties no cilv\u0113ku pulc\u0113\u0161an\u0101s viet\u0101m un riska grupu person\u0101m sabiedrisk\u0101s viet\u0101s lietot medic\u012bnisk\u0101s sejas maskas vai respiratorus. Person\u0101m ar elpce\u013cu infekcijas simptomiem ieteicams palikt m\u0101j\u0101s, sazin\u0101ties ar \u0123imenes \u0101rstu un iev\u0113rot \u0101rsta nor\u0101d\u012bjumus.<\/p>\n Nacion\u0101lais vesel\u012bbas dienests atg\u0101dina, ka gripas epid\u0113mijas laik\u0101 no valsts bud\u017eeta l\u012bdzek\u013ciem tiek apmaks\u0101tas \u0123imenes \u0101rstu m\u0101jas viz\u012btes pie gripas slimniekiem, ja pacients dz\u012bvo \u0101rsta pamatdarb\u012bbas teritorij\u0101. Pacientam par viz\u012bti j\u0101maks\u0101 tikai valst\u012b noteikt\u0101 pacienta iemaksa \u2013 2,85 eiro.<\/p>\n Avots: SPKC<\/p>\n","protected":false},"excerpt":{"rendered":"Latvij\u0101 turpin\u0101s gripas epid\u0113mija, un 2025. gada 51. ned\u0113\u013cas monitoringa dati liecina par turpm\u0101ku saslimst\u012bbas pieaugumu. Pacientu \u012bpatsvars…\n","protected":false},"author":2,"featured_media":89413,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[23,28,29,32,33,22,30,31,35,39,38,36,37,34,40,20,26,27,24,25,21],"class_list":{"0":"post-89412","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-aktualitates","8":"tag-aktualitates","9":"tag-breaking-news","10":"tag-breakingnews","11":"tag-featured-news","12":"tag-featurednews","13":"tag-headlines","14":"tag-latest-news","15":"tag-latestnews","16":"tag-latvia","17":"tag-latvian","18":"tag-latviesu","19":"tag-latviesu-valoda","20":"tag-latviesuvaloda","21":"tag-latvija","22":"tag-lv","23":"tag-news","24":"tag-popularakas-zinas","25":"tag-popularakaszinas","26":"tag-top-stories","27":"tag-topstories","28":"tag-zinas"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lv\/115806233071076758","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/89412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/comments?post=89412"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/posts\/89412\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media\/89413"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/media?parent=89412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/categories?post=89412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lv\/wp-json\/wp\/v2\/tags?post=89412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}